Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

For individuals with type 1 diabetes, intraindividual body weight variability, or body weight cycling, is associated with an ...

Symptoms of NAION can include blurred vision, peripheral vision loss, dark spots in vision, and changes in color perception. Though the exact mechanism is not fully understood, researchers hypothesize ...

Today, the American Diabetes Association® (ADA) announced the awardees of the 2025 Pathway to Stop Diabetes® (Pathway) grants ...

Scientists remain puzzled as to why some individuals taking popular weight loss ... that NAION risk was up to four times greater for those taking these medications to manage either diabetes ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Tirzepatide Shows Powerful Diabetes-Prevention Effect in Three-Year Trial Nov. 26, 2024 — Tirzepatide, a new injectable weight-loss drug, reduced the risk of diabetes in patients with obesity ...

They call for larger studies with more diverse participants to confirm their findings and explore why the risk appears different between diabetes and weight-loss patients. For now ...

Response Pharmaceuticals, Inc., a clinical-stage company focused on weight management and metabolic health in high-risk populations, today announced the early completion of enrollment in a Phase 2 ...